KEY FINDINGS The global cartilage degeneration market is expected to advance with a CAGR of 4. 64% over the forecasting years of 2021 to 2028. The market growth is primarily ascribed to factors such as degeneration of cartilage due to obesity, the prevalence of bone and joint-related diseases across the geriatric population, and the increasing number of sports injuries that damage cartilage and ligaments.
New York, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "GLOBAL CARTILAGE DEGENERATION MARKET FORECAST 2021-2028" - https://www.reportlinker.com/p06126743/?utm_source=GNW
Cartilage is a smooth, connective tissue cushioning the meeting area of joints and bones.Cartilage degeneration can lead to chronic inflammation in the joints.
The risk factors for cartilage denegation are accidental injury, weight, aging, sports injuries, or trauma to joints like knees or hips, among others.Cartilage regeneration is used to restore damaged cartilage.
Some of these procedures include arthroscopy, autologous chondrocyte implantation, microfracture, and matrix-induced autologous chondrocyte implantation.
Players and athletes frequently suffer due to injuries during sports activities.These injuries have substantial potential to damage ligaments and cartilage.
Therefore, an increasing number of sports injuries among players is expected to drive the growth of the cartilage degeneration market over the forecasting period.As per a study published by Stanford Children’s Health in 2020, an estimated 30 million children, as well as teenagers, participate in sports-related activities annually in the United States.
Furthermore, according to the approximations issued by the institution, organized sports observe nearly 3.5 million injuries per year in the country.
The global cartilage degeneration market growth assessment entails the evaluation of the Asia-Pacific, North America, Europe, and the Rest of World. The Asia-Pacific is expected to grow with the highest CAGR over the forecasted years owing to the increased expenditure on public health care systems, the rising acceptance of sports activities among the younger generation, and the augmenting geriatric populace.
The competition among the tier 1 companies and tier 2 and tier 3 companies is on the rise within the global cartilage degeneration market.The threat of rivalry is also high among market participants in their respective segments.
Moreover, vendors differentiate their products on the basis of cost, quality, and application.
Leading companies operating in the market are Smith & Nephew PLC, DePuy Synthes Companies, Arthrex Inc, Stryker Corporation, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
1. ANIKA THERAPEUTICS INC
2. ARTHREX INC
3. B BRAUN MELSUNGEN AG
4. BIOTISSUE SA
5. CARTIHEAL INC
6. CONMED CORPORATION
7. DEPUY SYNTHES COMPANIES
8. OSIRIS THERAPEUTICS INC
9. RTI SURGICAL INC
10. SMITH & NEPHEW PLC
11. STRYKER CORPORATION
12. VERICEL CORPORATION
13. ZIMMER BIOMET HOLDINGS
Read the full report: https://www.reportlinker.com/p06126743/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001